Wedbush Reiterates Outperform on Aquestive Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $4 price target.

October 10, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating and $4 price target on Aquestive Therapeutics.
The reiteration of an Outperform rating by a reputable analyst like Andreas Argyrides from Wedbush is a positive signal for AQST. It indicates that the analyst believes the company's stock will outperform the market, which could lead to an increase in its stock price. The maintained price target of $4 also suggests that the analyst sees potential for the stock's price to increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100